- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Medicenna Therapeutics Corp: Medicenna closes $20M investment from RA Capital | 1 | Stockwatch | ||
| Di | Medicenna Therapeutics Corp.: Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management | 1 | GlobeNewswire (USA) | ||
| 26.04. | Medicenna Therapeutics Corp: Medicenna arranges $20M private placement | 1 | Stockwatch | ||
| 26.04. | Medicenna Therapeutics Corp: Medicenna Therapeutics resuming at the open | 1 | Stockwatch | ||
| 26.04. | Medicenna Therapeutics Corp: Medicenna Therapeutics halted at the open | 1 | Stockwatch | ||
| 26.04. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management | 1 | GlobeNewswire (USA) | ||
| 25.04. | Medicenna Therapeutics Corp. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.04. | Medicenna Therapeutics Corp.: Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting | 81 | GlobeNewswire (Europe) | Oral presentation of MDNA11's Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity... ► Artikel lesen | |
| 10.04. | Medicenna Therapeutics Corp.: Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer | 75 | GlobeNewswire (Europe) | 100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H... ► Artikel lesen | |
| 09.04. | Medicenna Therapeutics Corp: Medicenna presents MDNA11 clinical data at AACR | 1 | Stockwatch | ||
| 09.04. | Medicenna Therapeutics Corp: Medicenna presents preclinical data on MDNA113 at AACR | 1 | Stockwatch | ||
| 09.04. | Medicenna shares preclinical data on treatment targeting tumours | 1 | The Market Herald Canada | ||
| 09.04. | Medicenna Therapeutics Corp.: Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) | 64 | GlobeNewswire (Europe) | MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the... ► Artikel lesen | |
| 04.04. | Medicenna Therapeutics Corp. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.04. | Stocks in Play: Medicenna Therapeutics Corp | - | Baystreet.ca | ||
| 06.03. | Medicenna Therapeutics Corp. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.03. | Medicenna Therapeutics Corp.: Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 14.02. | Medicenna Therapeutics Corp: Medicenna Therapeutics' Dec. 31 cash at $21.8 million | 1 | Stockwatch | ||
| 14.02. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update | 138 | GlobeNewswire (Europe) | With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint... ► Artikel lesen | |
| 13.02. | Medicenna Therapeutics Corp: Medicenna doses first patient in combo Ability-1 study | 1 | Stockwatch |
Seite:
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,575 | -3,37 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,045 | +4,50 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,946 | +9,75 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 23,130 | +1,80 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| ONCOLYTICS BIOTECH | 1,090 | +1,87 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 1,025 | +1,49 % | Assertio Holdings Q1 2024 Earnings Preview | ||
| SIGA TECHNOLOGIES | 10,150 | +7,52 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,000 | -0,20 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 10,390 | +13,18 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,410 | +4,23 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,750 | +3,07 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,610 | -1,88 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 12,330 | +3,35 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
MEDICENNA THERAPEUTICS CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,161 Euro und damit +2,55 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
